As part of our Special SBS Alumni Seminar Series, we have invited Dr Ignacio Asial, our PhD (Research) Programme alumni to share his experience from academia to bioentrepreneurship.
Dr. Ignacio Asial is now the CEO and Founder of DotBio, a Singapore-born biopharma company specialized in next-generation antibody therapies. He is also an Adjunct Assistant Professor at Nanyang Technological University.
Prior to launching DotBio, Dr. Asial held diverse scientific positions. He worked in academia in institutions such at NTU, UCSF, and Centre National de la Recherche Scientifique, as well as in the private sector at Ambrilia Biopharma and Genentech.
Dr. Asial obtained a M. Eng. in Biotechnology from Ecole Supérieure d’Ingénieurs de Luminy / Polytech Marseille, a M.Sc. in Biochemistry, Structural Biology, Bioinformatics and Genomics from Aix-Marseille University, and a Ph.D. in Biological Sciences from NTU. He specializes in technology development, in particular in the fields of antibody engineering and directed evolution.